Kym Mcnicholas On Innovation

For the first time in over TWO DECADES, there's a new medication treatment approach for peripheral artery disease! The groundbreaking STRIDE Trial has shown that semaglutide significantly improves walking ability and quality of life for those suffering from PAD with type 2 diabetes. JOIN US THURSDAY as we interview Dr. Marc Bonaca, co-investigator of this landmark study that revealed: ✅ 40-meter improvement in walking distance ✅ Significant quality of life benefits ✅ 54% reduction in disease progression requiring intervention ✅ Benefits potentially extending beyond weight loss This could be life-changing for millions who struggle with leg pain that limits everyday activities. Have questions about what this means for your PAD treatment? Drop them below and Dr. Bonaca will address them during our exclusive interview! #PADBreakthrough #DiabetesCare #STRIDETrial #PatientVoices #MedicalAdvancement #semaglutitude #ozempic #ozempicwalking #wegovywalking #wegovysupport #markbonaca #globalpadassociation #peripher